Mylotarg (Gemtuzumab Ozogamicin)

gemtuzumab ozogamicin, the active ingredient in Mylotarg, is an antibody‑drug conjugate presented as a powder for concentrate for solution for infusion for intravenous use. It is indicated for the treatment of acute myeloid leukemia in patients whose leukemic cells express the CD33 antigen.

GNH USA supplies Mylotarg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The product complies with EU regulatory standards and is distributed under strict quality controls.

Mylotarg is used in the management of CD33‑positive acute myeloid leukemia, an aggressive hematologic malignancy.

Acute myeloid leukemia (newly diagnosed): used in combination with standard chemotherapy to improve remission rates. Relapsed or refractory AML: provides a targeted option for patients who have not responded to prior therapy. CD33‑positive AML in patients not eligible for intensive chemotherapy: offers a less intensive treatment alternative.

Mylotarg may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Fatigue or weakness - Fever and chills - Headache - Infusion‑related reactions (e.g., flushing, rash) - Cytopenias such as neutropenia and thrombocytopenia

Serious or Rare Side Effects: - Hepatic veno‑occlusive disease (VOD) - Severe infections due to profound myelosuppression - Life‑threatening bleeding events - Tumor lysis syndrome - Pulmonary toxicity (e.g., interstitial pneumonitis) - Anaphylactic or severe allergic reactions

Before initiating therapy, clinicians should assess baseline organ function and monitor patients closely during treatment.

Monitor blood counts: perform regular CBC to detect cytopenias. Assess liver function: check hepatic enzymes before and during therapy. Evaluate for VOD risk: avoid in patients with prior liver disease or high bilirubin. Use prophylactic antimicrobials: reduce infection risk associated with myelosuppression. Avoid concurrent strong CYP3A4 inducers: may alter calicheamicin exposure. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mylotarg can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent use with other hepatotoxic agents: increased risk of liver injury. - Combination with strong CYP3A4 inducers: may reduce efficacy of the calicheamicin payload. - Co‑administration with other myelosuppressive chemotherapy: heightened cytopenia risk.

Moderate Interactions (Monitor Closely): - Azole antifungals: may increase exposure, monitor liver function. - Warfarin or other anticoagulants: potential alteration of INR, monitor coagulation parameters.